Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Affimed NV AFMD

Healthcare Biotechnology
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1... see more

Recent & Breaking News (NDAQ:AFMD)

Affimed to Present at the BIO CEO & Investor Conference and at the Leerink Partners Global Healthcare Conference

GlobeNewswire February 3, 2015

Affimed N.V. (Nasdaq: AFMD) to Ring The Nasdaq Stock Market Opening Bell

GlobeNewswire January 29, 2015

Affimed Appoints Dr. Martin Treder as Chief Scientific Officer

GlobeNewswire January 20, 2015

Affimed Receives EUR 2.4 million ($3 million) Research Grant from German Government to Fund Trispecific Abs

GlobeNewswire January 7, 2015

Affimed Presents Final Data for AFM13 Phase 1 Trial at ASH

GlobeNewswire December 8, 2014

Affimed Reports Financial Results for Third Quarter 2014

GlobeNewswire November 18, 2014

Affimed to Present at the Jefferies Global Healthcare Conference - London

GlobeNewswire November 12, 2014

Affimed Announces Third Quarter 2014 Financial Results Conference Call

GlobeNewswire November 11, 2014

Affimed Announces Closing of Initial Public Offering

GlobeNewswire September 17, 2014